Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: A single-center retrospective study

Table 2 Insulin resistance change in 30 active rheumatoid arthritis patients naïve to biologics by tofacitinib therapy

Group	Before	After	P value1
All (n = 30)
DAS28	6.291 ± 0.530 (5.16-7.37)	3.101 ± 0.522 (2.08-4.21)	< 0.001
Decrease in DAS28		3.194 ± 0.609 (1.94-4.36)
HOMA-IR	2.639 ± 1.185 (1.07-5.89)	1.947 ± 0.714 (0.98-4.19)	< 0.001
QUICKI	0.3353 ± 0.0222 (0.296-0.380)	0.3492 ± 0.0183 (0.310-0.385)	< 0.001
High IR (n = 18)
DAS28	6.499 ± 0.472 (5.56-7.37)	3.006 ± 0.444 (2.52-4.21)	< 0.001
Decrease in DAS28		3.499 ± 0.536 (2.36-4.36)
HOMA-IR	3.331 ± 1.036 (2.04-5.89)	2.292 ± 0.707 (1.21-4.19)	< 0.001
QUICKI	0.3207 ± 0.0135 (0.296-0.343)	0.3397 ± 0.0154 (0.310-0.372)	< 0.001
Low IR (n = 12)
DAS28	5.980 ± 0.470 (5.16-6.69)	3.244 ± 0.614 (2.08-3.99)	< 0.001
Decrease in DAS28		2.736 ± 0.389 (1.94-3.23)
HOMA-IR	1.602 ± 0.294 (1.07-2.00)	1.430 ± 0.293 (0.98-2.02)	0.139
QUICKI	0.3573 ± 0.0117 (0.344-0.380)	0.3634 ± 0.0122 (0.343-0.385)	0.156

¹Before vs after TOF therapy.

HOMA-IR: Homeostatic model assessment-insulin resistance; QUICKI: Quantitative Insulin Sensitivity Check Index; DAS28: Disease Activity Score 28.